ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

41.40
0.00
( 0.00% )
Updated: 07:47:04
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
41.40
Bid
42.20
Offer
42.60
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.8-4.1666666666743.2474319244.19451697DE
4-8.6-17.25051.540.411744.74603537DE
12-3.8-8.4070796460245.251.540.412747.17167127DE
26-6.8-14.107883817448.257.540.415948.57608533DE
5218.4802358.521.39999917344.34418355DE
15617.673.949579831923.858.51916742.00023485DE
26017.673.949579831923.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0598 €
(67.04%)
2.1M
A6NAsana Inc
21.00 €
(43.84%)
19.06k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
35JCanaan Inc
2.82 €
(31.78%)
135k
AXIAtos SE
0.0028 €
(-98.58%)
1.55B
M0YNMynaric AG
1.35 €
(-73.63%)
293.06k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.55B
D7GNel ASA
0.2624 €
(-1.72%)
4.22M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.48 €
(2.07%)
2.14M
TE9Teco 2030 ASA
0.0598 €
(67.04%)
2.1M

Discussion

View Full Feed
TenKay TenKay 5 minutes ago
I am fascinated by the penny stock psyche and have an addiction to iHub…although that us wained a lot since the OTC got a lot more boring with the changes to 15c2-11.
HMBL
Drugdoctor Drugdoctor 5 minutes ago
Shares below .01 about gone!
FORW
novicetrader novicetrader 5 minutes ago
ASTS-that's another beauty in the Space group. Quite a bit of steam still left in this sector I think.
ASTS
MR, MR, 5 minutes ago
Anyone left here are officially bag holders. Reggie news was just another attempt to avoid, deflect and then come up with something new. Same old same old BS just different players?? I question that.
MONI
arizona1 arizona1 5 minutes ago
Do you know what a link is? Because you didn't supply one, which was the question.
Curt D Curt D 5 minutes ago
Agreed. Of course there will always be those flipping, but soon it's going to move quickly and they'll have little affect.
RDAR
HoldEm777 HoldEm777 5 minutes ago
Retrace coming….to vertical on the 3rd. Probably Monday
RDAR
IB_ IB_ 5 minutes ago
That stupid number just goes to show what goes on in the head of a disciple of nasrat !!!!!!!!!

We all know that nasrat has REPEATEDLY loaned and talked about loaning Elite money if and when Elite needed it, but yet he chose to grab this gem for himself ......... That is NOT acting in
ELTP
koolmc koolmc 5 minutes ago
otc got the volume back and .0000's running everyone should tweet and push the company to follow through next week.
ICTY
Hawk05 Hawk05 5 minutes ago
it's called a rental program.  Maybe the program guarantees a working device for an entire year.
BIEL
georgie18 georgie18 5 minutes ago
Your very welcome...🥳
knrorrel knrorrel 6 minutes ago
$FORW  tic tac  🚀🚀🚀🚀 $GVSI toooo 🚀🚀🚀🚀
is 2025 that OTC YEAR ?  inquire now, with collecting ? 😂

FORW GVSI
koolmc koolmc 6 minutes ago
gvsi .0034
threewheeler threewheeler 6 minutes ago
KRTL next week can be explosive more updates expected
KRTL
gdog gdog 6 minutes ago
filled .92812
NLST
knrorrel knrorrel 6 minutes ago
$FORW  tic tac  🚀🚀🚀🚀 $GVSI toooo 🚀🚀🚀🚀
is 2025 that OTC YEAR ?  inquire now, with collecting ? 😂

FORW GVSI
JoJr JoJr 6 minutes ago
Chasing would not be fun!
RDAR
splintered sunlight splintered sunlight 7 minutes ago
CHYI was/is baffling.

Not complaining though!!!!!!
CHYI
dstock07734 dstock07734 7 minutes ago
Sorry. No time for lightweight. I have a bunch of your buddies on the ignore list and you can have fun with them.
NWBO
Idiot Mayor Idiot Mayor 7 minutes ago
Another cocky sucker buys at .0008, says “See ya at .005!!!!!!” and INSTANTLY loses 20%…..😂😂😂😂😂😂😂😂😂😂

The other gambler is now down over half!

Ya’ll just REFUSE to learn, don’t ya???
DBMM
Curt D Curt D 7 minutes ago
Indeed!
RDAR
pual pual 7 minutes ago
post 51654
I at least have the honesty to ask questions instead of just looking (during 3 years) at scenarios that never materialize notwithstanding my obviously vengefull vendetta.
The positive development: The company still operate and duly report (cannot be negated even by you)
GRST
Louie_Louie Louie_Louie 7 minutes ago
Thanks Queen. I hope you're not trading this too much right now. These last couple days it's doing it's penny's climb, building for another rug pull again.
linkvest linkvest 7 minutes ago
Riding the wave buddy...
IGPK
work-n-hard work-n-hard 7 minutes ago
LGHL: Watch for possible move into close.
LGHL

Your Recent History

Delayed Upgrade Clock